Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

91.95USD
2:25pm EST
Change (% chg)

$3.42 (+3.86%)
Prev Close
$88.53
Open
$90.27
Day's High
$92.08
Day's Low
$88.56
Volume
494,064
Avg. Vol
443,666
52-wk High
$100.50
52-wk Low
$80.10

Chart for

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $15,547.75
Shares Outstanding(Mil.): 175.62
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

BRIEF-Biomarin Sells Second Priority Review Voucher For $125 Mln

* BIOMARIN SELLS SECOND PRIORITY REVIEW VOUCHER FOR $125 MILLION

Nov 27 2017

BRIEF-Biomarin reports Q3 loss $0.07/shr

* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

Oct 26 2017

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

Oct 26 2017

BRIEF-Biomarin Pharmaceutical: Increased board size from nine to ten members​

* Biomarin Pharmaceutical says ‍on September 28, 2017, board of directors of increased size of board from nine to ten members​ - SEC filing Source: (http://bit.ly/2yWOHiP) Further company coverage:

Oct 03 2017

BRIEF-FDA not planning to hold advisory committee meeting for Biomarin's Pegvaliase BLA

* FDA not currently planning to hold advisory committee meeting for Biomarin's Pegvaliase Biologics License Application (BLA)

Sep 14 2017

BRIEF-FDA accepts Biomarin's Pegvaliase Biologics License Application

* FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation

Aug 29 2017

BRIEF-BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes

* BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024

Aug 07 2017

BRIEF-Biomarin announces offering of $450 mln of senior subordinated convertible notes due 2024

* Biomarin announces offering of $450 million of senior subordinated convertible notes due 2024

Aug 07 2017

BRIEF-BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational gene therapy for Hemophilia A, into phase 3 studies

* BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational Gene Therapy For Hemophilia A, into phase 3 studies

Aug 02 2017

BRIEF-Sarepta and Biomarin report execution of global settlement

* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation

Jul 18 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.08 +0.43
Pfizer Inc. (PFE.N) $36.46 -0.18
Novartis AG (NOVN.S) CHF83.85 --
Merck & Co., Inc. (MRK.N) $56.01 -0.90
Roche Holding Ltd. (ROG.S) CHF241.70 0.00
Roche Holding Ltd. (RO.S) CHF242.50 -0.70
Abbott Laboratories (ABT.N) $55.38 +0.65
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.77 -0.89

Earnings vs. Estimates